Document is current
Any future updates will be listed below
-
Authors
Giordano, Giorgia
Merlini, Alessandra
Capozzi, Federica
Ferrero, Giulio
Tucciarello, Cristina
Majidi, Shahab
Comparato, Simona
Mesiano, Giulia
Liuzzi, Elisabetta
Galvagno, Federica
Massa, Annamaria
Brusco, Silvia
Leuci, Valeria
Riganti, Chiara
Cutrupi, Santina
De Bortoli, Michele
D’Ambrosio, Lorenzo
Sangiolo, Dario
Grignani, Giovanni
Pignochino, Ymera
- License Information
-
More Information
Article History
Received: 16 April 2025
Accepted: 30 July 2025
First Online: 23 September 2025
Declarations
:
: AMe: PharmaMar, support for meeting participation and Institutional Grant LDA: PSI CRO Italy, GSK, AstraZeneca, Eisai, and Boehringer Ingelheim, Advisory Board; support for meeting participation from PharmaMar and AstraZeneca. GGr: fees for consulting and advisory board roles from PharmaMar, Lilly, Novartis, GSK, Bayer, and Eisai. LDA: PSI CRO Italy, GSK, AstraZeneca, Eisai, and Boehringer Ingelheim, Advisory Board; support for meeting participation from PharmaMar and AstraZeneca. GGr: fees for consulting and advisory board roles from PharmaMar, Lilly, Novartis, GSK, Bayer, and Eisai.
: Not applicable.Ethical approval and consent to participate.All participants provided written informed consent in accordance with a protocol that adheres to the Declaration of Helsinki, and the study was approved by the local Institutional Review Board and Ethics Committee (approval number 296–2020/14-OCT-2020). Animal study was approved by the Institutional Animal Welfare Organization (OPBA) of the Candiolo Cancer Institute according to Italian Legislative Decree no. 26 of 03.14.2014 and by the Italian Ministry of Health (Aut. Min. 178/2015-PR).
